Last reviewed · How we verify
Durvalumab, Tremelimumab and ,FOLFOX — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Durvalumab, Tremelimumab and ,FOLFOX (Durvalumab, Tremelimumab and ,FOLFOX) — Centre Georges Francois Leclerc.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Durvalumab, Tremelimumab and ,FOLFOX TARGET | Durvalumab, Tremelimumab and ,FOLFOX | Centre Georges Francois Leclerc | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Durvalumab, Tremelimumab and ,FOLFOX CI watch — RSS
- Durvalumab, Tremelimumab and ,FOLFOX CI watch — Atom
- Durvalumab, Tremelimumab and ,FOLFOX CI watch — JSON
- Durvalumab, Tremelimumab and ,FOLFOX alone — RSS
Cite this brief
Drug Landscape (2026). Durvalumab, Tremelimumab and ,FOLFOX — Competitive Intelligence Brief. https://druglandscape.com/ci/durvalumab-tremelimumab-and-folfox. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab